VedaBio vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
Precision genome editing biotech developing base and prime editors for rare genetic diseases; improved specificity over first-generation CRISPR competing with Beam Therapeutics and Intellia.
About
Veda Bio is a biotechnology company developing novel therapeutics for rare genetic diseases and cancer using its proprietary precision genome editing platform — enabling targeted genetic corrections with greater specificity and reduced off-target editing compared to first-generation CRISPR tools. Founded in 2019 and headquartered in Seattle, Washington, Veda Bio was founded by genome editing pioneers and has raised early-stage funding to develop its differentiated editing technology platform.\n\nVeda Bio's platform focuses on delivering precision genetic medicine that can address root causes of genetic diseases rather than managing symptoms. The company's approach aims to improve on first-generation CRISPR-Cas9 by developing base editors and prime editors that can make specific genetic corrections (single letter DNA changes, small insertions or deletions) without introducing double-strand DNA breaks that create higher off-target editing risk. This precision is critical for therapeutic applications where off-target genomic changes could have serious safety consequences.\n\nIn 2025, Veda Bio operates in the competitive genome editing therapeutics space alongside Intellia Therapeutics, Beam Therapeutics (base editing pioneer), Prime Medicine, and CRISPR Therapeutics. The genome editing field experienced a landmark moment in 2023 with the FDA approval of Casgevy (the first CRISPR-based therapy, for sickle cell disease and beta-thalassemia, developed by Vertex and CRISPR Therapeutics) — validating the genome editing therapeutic modality and creating competitive pressure for improved precision editing platforms. Veda Bio's 2025 strategy focuses on advancing lead programs in rare genetic indications through preclinical development toward IND applications, publishing research to establish scientific credibility, and exploring partnerships or licensing with larger biopharmaceuticals for clinical development.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.